Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors

NCT01609556 is registered in ClinicalTrials.gov with ImmunoGen, Inc. as lead sponsor.

NCT NCT01609556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01609556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
Lead sponsor
ImmunoGen, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 28, 2012
Completion date
March 19, 2018
Enrollment
206 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

tumors